Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony‑stimulating factor presented as a sterile solution for intravenous and subcutaneous use. It stimulates neutrophil production to reduce the duration of severe neutropenia in patients receiving myelosuppressive chemotherapy and in other neutropenic conditions.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide through a robust cold‑chain distribution network.

Filgrastim (Neupogen) is a granulocyte colony‑stimulating factor used to manage neutrophil‑deficiency conditions.

- Chemotherapy‑induced neutropenia: reduces the duration of severe neutropenia and lowers infection risk in cancer patients. - Peripheral blood stem cell mobilization: enhances collection of CD34+ stem cells for autologous transplantation. - Severe congenital neutropenia: increases neutrophil counts in patients with inherited neutropenia disorders. - Myelodysplastic syndrome‑related neutropenia: improves neutrophil recovery during treatment. - HIV‑associated neutropenia: supports neutrophil production in patients with HIV‑related marrow suppression.

Filgrastim may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Bone pain: aching discomfort in the limbs or back. - Injection site reactions: redness, swelling, or mild tenderness. - Fever: transient elevated body temperature. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain and shock. - Acute respiratory distress syndrome: severe breathing difficulty. - Anaphylaxis: rapid onset of allergic symptoms such as hives, swelling, and airway compromise. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Leukocytosis: excessively high white blood cell count. - Capillary leak syndrome: fluid accumulation and low blood pressure.

Before using Filgrastim, several precautions should be considered to ensure safe administration.

- Dose adjustment in renal or hepatic impairment: monitor blood counts and adjust as needed. - Monitor complete blood count: assess neutrophil response and detect leukocytosis. - Use with caution in patients with sickle cell disease: increased risk of vaso‑occlusive events. - Avoid in individuals with known hypersensitivity to filgrastim or any excipients: discontinue if allergic reaction occurs. - Pregnancy and lactation: safety not established; weigh potential benefits against unknown risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use of other colony‑stimulating factors: may cause excessive leukocytosis. - High‑dose corticosteroids: can blunt the neutrophil‑stimulating effect of filgrastim. - Chemotherapy agents with overlapping myelosuppressive activity: may reduce the intended benefit of filgrastim.

Moderate Interactions (Monitor Closely): - Antibiotics: may mask signs of infection, requiring careful clinical monitoring. - Live vaccines: immune response may be altered; avoid simultaneous administration. - ACE inhibitors or angiotensin receptor blockers: potential increased risk of capillary leak syndrome. - Immunosuppressants (e.g., cyclosporine): may affect neutrophil recovery dynamics.